Sanofi Under Fire by Senate Panel For Competition Delaying Tactics

Sanofi contributed more than $5 million to two medical groups and a researcher as part of a coordinated campaign to delay the approval of generic alternatives to Lovenox, the company's blockbuster blood-thinner, a U.S. Senate Finance Committee investigation has found.

Read more of this story from here.

More News:

All news »

What are your comments?

Join the discussion today. Login Here.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments